Main Uses of Celecoxib Cinfa

Celecoxib Cinfa belongs to a group of medicines known as non-steroidal anti-inflammatory drugs (NSAIDs), specifically a sub-group called cyclo-oxygenase-2 (COX-2) inhibitors. This medication is primarily used to reduce pain and inflammation in patients suffering from various joint and bone conditions.

Osteoarthritis

Celecoxib Cinfa is indicated for the symptomatic relief of osteoarthritis. This is a chronic condition characterized by the gradual breakdown of joint cartilage, which can lead to pain, stiffness, and reduced mobility in the affected joints.

Rheumatoid Arthritis

This medication is used to manage the symptoms of rheumatoid arthritis. This is an autoimmune disease where the immune system attacks the lining of the joints, causing inflammation, swelling, and chronic pain that can lead to joint deformity over time.

Ankylosing Spondylitis

Celecoxib Cinfa is also used to treat ankylosing spondylitis. This is an inflammatory disease that, over time, can cause some of the small bones in the spine to fuse. This fusing makes the spine less flexible and can result in a hunched-forward posture.

Benefits and Mechanism of Action

The primary benefit of this medication is its ability to target inflammation and pain more specifically than some traditional NSAIDs.

Targeting Inflammation

In the body, enzymes called cyclo-oxygenases produce prostaglandins. Some prostaglandins cause pain and inflammation, while others protect the stomach lining. Celecoxib Cinfa works by selectively inhibiting the COX-2 enzyme, which is primarily responsible for producing the prostaglandins that cause inflammation and pain.

Symptom Management

By reducing the production of inflammatory prostaglandins, the medication helps to:

• Decrease joint pain and tenderness.
• Reduce swelling and inflammation in the affected areas.
• Improve physical function and mobility in patients with chronic joint conditions.
• Alleviate stiffness, particularly the morning stiffness often associated with inflammatory arthritis.

Regulatory References

1. NIH MedlinePlus Drug Information overview

Official Eligibility Status

Celecoxib Cinfa use is generally permitted for adult patients across its labeled uses. The medicine is also approved for pediatric patients aged two years and older, specifically for the management of Juvenile Rheumatoid Arthritis. Safety and efficacy, however, have not been established for children younger than two years of age.

Populations Strictly Contraindicated

Official regulatory documents prohibit the use of this medicine in several groups:

• Individuals with a known hypersensitivity to celecoxib, any capsule component, or sulfonamides.
• Patients with a history of allergic reactions to aspirin or other NSAIDs.
• Treatment of peri-operative pain during Coronary Artery Bypass Graft (CABG) surgery.
• Pregnant women starting at 30 weeks of gestation and later.
• Patients with active gastrointestinal bleeding, severe hepatic impairment (Child-Pugh Class C), severe renal impairment (creatinine clearance less than 30 mL/min), or established ischaemic heart disease and advanced heart failure.

Conditional Use and Restrictions

Eligibility is restricted for those with moderate hepatic impairment (Child-Pugh Class B), requiring a reduction in the maximum dose. Caution is advised for older adults and patients with low body weight, where initiation at the lowest recommended dose is specified.

Interactions with other medicines and products

Celecoxib should not be taken with other nonsteroidal anti-inflammatory drugs (NSAIDs), including common pain relievers like ibuprofen or naproxen, as this significantly raises the risk of gastrointestinal side effects such as bleeding or ulcers.

Anticoagulants and Antiplatelet Agents: Concomitant use with blood thinners (e.g., warfarin) or antiplatelet drugs (e.g., analgesic doses of aspirin) increases the risk of serious bleeding events. Close monitoring of coagulation status is required when celecoxib therapy is initiated or changed in patients taking warfarin.

Blood Pressure Medications: Celecoxib may reduce the effectiveness of certain antihypertensive drugs, including ACE inhibitors, Angiotensin Receptor Blockers (ARBs), and diuretics (water pills). The combination with ACE inhibitors or ARBs, particularly in elderly or volume-depleted patients, increases the risk of impaired kidney function and requires careful monitoring.

Other Important Interactions: Celecoxib can increase the serum levels and potential toxicity of drugs like Lithium and Digoxin, necessitating dose adjustments and monitoring. Use with CYP2C9 inhibitors (e.g., fluconazole) may increase celecoxib exposure, while combination with corticosteroids or certain antidepressants (SSRIs/SNRIs) also increases the risk of gastrointestinal bleeding.

The active ingredient, celecoxib, functions as a selective inhibitor of the Cyclooxygenase-2 ( COX-2) enzyme. This inhibition occurs through the drug's binding to a unique pocket within the COX-2 structure, which blocks the enzyme's capacity to process its substrate, arachidonic acid. The mechanism primarily affects the COX-2 found at sites of increased physiological signaling rather than the COX-1 enzyme involved in constitutive physiological functions.

Inhibition of COX-2 disrupts the Arachidonic Acid Cascade, halting the synthesis of lipid mediators known as prostanoids, especially Prostaglandin E2 ( PGE2). This reduction in PGE2 levels prevents the chemical sensitization of peripheral nociceptive nerve endings and dampens the excitability of neural pathways. The mechanism also involves a functional constraint: it suppresses COX-2-derived Prostacyclin ( PGI2) while relatively sparing COX-1-derived Thromboxane ( TXA2). This differential effect influences the balance of prostanoids in vascular tissue. The simultaneous action on central thermoregulation contributes to overall physiological changes.

How to Use Celecoxib Cinfa

Celecoxib Cinfa is a hard capsule intended for oral administration, with usage governed by standardized guidelines concerning dose, frequency, and duration. The medication may be taken with or without food.

---

Official Dosing and Frequency Patterns

The required daily dosage and frequency are dependent on the condition being addressed, but are consistently administered in doses of 100 mg or 200 mg capsules. For conditions such as Osteoarthritis and Ankylosing Spondylitis, the typical total daily dose is 200 mg, administered either once daily (OD) or in two divided 100 mg doses. Rheumatoid Arthritis requires two divided doses of 100 mg to 200 mg daily. The maximum dose for most indications is capped at 400 mg per day.

---

Administration Requirements and Duration Principle

If the capsule cannot be swallowed whole, its contents may be sprinkled onto a level teaspoon of specific approved foods, such as applesauce or yogurt, and must be swallowed immediately with fluid. The overarching principle for all use is to employ the lowest effective dosage for the shortest duration possible to achieve the necessary support.

---

Population-Specific Use

Official labeling mandates dose modifications for specific patient groups. For adults with moderate hepatic impairment or those identified as CYP2C9 poor metabolizers, the recommended starting dose should be reduced by 50%. For Juvenile Rheumatoid Arthritis in patients aged 2 years or older, dosing is determined by body weight, requiring 50 mg or 100 mg twice daily. If a dose is missed, instructions state that the next dose should be taken at the regularly scheduled time, and a forgotten dose should not be compensated for by taking a double dose.

Recent Clinical Evidence Overview

This summary provides descriptive insights from research into celecoxib's clinical use and profile, focusing only on study observations rather than interpretation or recommendations.

---

Efficacy and Primary Observations

Clinical trials have evaluated celecoxib's effect in conditions such as osteoarthritis (OA) and rheumatoid arthritis (RA). Research compared outcomes against a placebo and against some non-selective non-steroidal anti-inflammatory drugs (NSAIDs).

• Symptom Impact: Studies documented improvements in self-reported pain scores and certain clinical symptoms in patients with RA and OA when celecoxib was compared to a placebo.
• Comparative Effects: Celecoxib was observed to be non-inferior to certain traditional NSAIDs in managing pain and improving clinical symptoms in RA and OA patients in several trials.

---

Safety Profile and Comparative Data

The safety profile of celecoxib has been a primary focus of comparative research, particularly regarding gastrointestinal (GI) and cardiovascular outcomes.

• Gastrointestinal Safety: Multiple reviews and trials consistently found celecoxib to be associated with a lower risk of gastroduodenal ulcers and related adverse GI events compared to non-selective NSAIDs.
• Cardiovascular Safety: A long-term, large-scale randomized trial (PRECISION) comparing celecoxib to ibuprofen and naproxen in patients with arthritis and cardiovascular risk factors found that the rates of cardiovascular events were generally similar between celecoxib and the comparator drugs at the doses studied. Research suggests that all NSAIDs, including celecoxib, carry a dose-related risk for cardiovascular events.

Observation Area	Comparative Trial Findings (vs. traditional NSAIDs)
GI Events	Lower risk of gastroduodenal ulcers was observed.
Renal Events	Fewer clinically significant renal events were observed at the doses studied (PRECISION trial).
Cardiovascular Risk	Similar rates of thrombotic events were observed in high-risk patients.

Key Studies & References

1. Celecoxib versus non-selective non-steroidal anti-inflammatory drugs for the prevention of recurrent bleeding in patients with aspirin use

Common questions about Celecoxib Cinfa (FAQ)

---

Q: How long does it take for Celecoxib Cinfa to start working?

According to official product information, celecoxib is rapidly absorbed after the capsule is taken. Official data indicates that celecoxib reaches its highest concentration (peak concentration) in the blood approximately 2 to 3 hours after a dose. This pharmacokinetic measurement reflects how the body processes the drug and is not a direct statement about when an individual patient will experience symptomatic relief.

---

Q: Is it safe to drink alcohol while taking Celecoxib Cinfa?

Regulatory documents state that using celecoxib in patients who consume three or more alcoholic drinks per day is associated with an increased potential for developing serious gastrointestinal side effects, such as stomach bleeding. This combination is linked to an increased potential for these effects, according to official warnings.

How to Store and Dispose of Celecoxib Cinfa

Celecoxib capsules must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), according to regulatory labeling. The medicine should be kept in its original, tightly closed container, and storage must be away from excess heat and moisture. It is required that the product not be refrigerated or frozen.

• The medication must be kept out of the reach and sight of children, and safety caps must remain locked.
• If capsule contents are mixed with applesauce, they are stable for up to six hours under refrigeration; however, if mixed with mashed banana, they must be ingested immediately.
• Disposal of all unused or expired medicine must be executed in accordance with local regulations as specified by a pharmacist, and should not be flushed or disposed of in wastewater.